



August Formulary Update

Effective August 14, 2025

New Formulary Medications

- atomoxetine (STRATTERA) oral tablets: previously formulary restricted
- indomethacin (INDOCID) suppositories: previously discontinued from market
- lisdexamfetamine (VYVANSE) oral capsules: previously formulary restricted

New Formulary Restricted Medications

- BC Cancer: addition of following medications restricted to the indications outlined in the BC Cancer Benefit Drug List and to patients who are registered with BC Cancer
 - atezolizumab (TECENTRIQ) injection
 - relugolix (ORGOVYX) oral tablets
- cenobamate (XCOPRI) oral capsule: restricted to PharmaCare criteria *OR* continuation of therapy for patients taking cenobamate oral solid prior to admission

Updates to Formulary Restricted Medications

- lactobacillus reuteri (BIOGAIA) oral drops: *name change* to limosilactobacillus reuteri (BIOGAIA PROTECTIS BABY DROPS) oral solution
- micafungin (MYCAMINE) injection criteria expanded to reflect current practice. Full details found on MyNH formulary listing.
- oseltamivir (TAMIFLU) oral capsule criteria amended, detailing more specific restriction criteria. Full details found on MyNH formulary listing.

Discontinued Medications

- acyclovir (ZOVIRAX) oral suspension
- enfuvirtide (FUZEON) injection
- gonadorelin (LUTREPULSE) injection
- nilutamide (ANANDRON) oral solid

August 14, 2025 For the information of physicians, nurses, and pharmacists. PLEASE POST	Formulary Changes	✓	For further information contact: <i>Jessica Granberg</i> Medication Use Management Pharmacists mumpharmacist@northernhealth.ca
	Drug Discontinuation		
	Medication Change		